In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent…
Martin Lee, author of Smoke Signals, and director of Project CBD, explains his motivations for pursuing cannabinoid research and his interest in the social history of marijuana. He explains the challenge…
By Will Boggs, MD NEW YORK (Reuters Health) –In mice, treatment with tumor necrosis factor (TNF) or lymphotoxin makes the blood-brain barrier (BBB) selectively permeable at metastasis sites,…
Nancy Simonian, MD, CEO, Syros Pharmaceuticals details the research of Richard A. Young of the Whitehead Institute and his discovery of super-enhancers, large groups of transcriptional enhancers that drive expression…
Nancy Simonian, MD, CEO, Syros Pharmaceuticals elaborates on the breakthrough discovery of super-enhancers, large groups of transcriptional enhancers that drive expression of genes that define cell identity. By identifying…
By Will Boggs, MD NEW YORK (Reuters Health) – Median survival of patients with metastatic gastric cancer has not improved, despite increased use of chemotherapy, researchers from The…
HIV infection attacks the immune system. In many parts of Africa, patients with HIV infection, also have vitamin deficiencies. A new study examined whether giving a multivitamin and…
By Will Boggs, MD NEW YORK (Reuters Health) – Improved survival among women with stage I or II endometrial cancer who undergo radiotherapy and lymphadenectomy may be attributable…
By Will Boggs, MD NEW YORK (Reuters Health) – Some patients with gastrointestinal stromal tumors (GIST) may benefit from resuming imatinib even after a previous failure of imatinib…
NEW YORK (Reuters Health) – Breast cancer metastases in a given patient often have a different receptor status, a new study demonstrates. “Different metastases within the same patient…
NEW YORK (Reuters Health) – A review of the literature has shown that the most important harms from cancer screening are often not quantified in screening trials. “Healthcare…
